MiR-221 facilitates the TGFbeta1-induced epithelial-mesenchymal transition in human bladder cancer cells by targeting STMN1 Urological oncology

BMC Urology

Volumn 15, Issue 1, 2015, Pages

  Liu, Jun ^a   Cao, Jian ^a   Zhao, Xiaokun ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Bladder cancer; EMT; miR 221; STMN1; TGF 1

Indexed keywords

FIBROACTIN PROTEIN; MEMBRANE PROTEIN; MICRORNA 221; NERVE CELL ADHESION MOLECULE; STATHMIN; STMN1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; MICRORNA; MIRN221 MICRORNA, HUMAN; STMN1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA BINDING; STMN1 GENE; UPREGULATION; ANTAGONISTS AND INHIBITORS; BLADDER TUMOR; DISEASE COURSE; DRUG EFFECTS; PATHOPHYSIOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL CULTURE; TUMOR INVASION; WOUND HEALING;

DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; STATHMIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; WOUND HEALING;

EID: 85043293136     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/s12894-015-0028-3     Document Type: Article

References (32)

1. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 2008;218:12-20.
2. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331(6024):1559-64.
3. Ha GH, Kim JL, Breuer EK. TACC3 is essential for EGF-mediated EMT in cervical cancer. PLoS One. 2013;8(8):e70353.
4. Creighton CJ, Chang JC, Rosen JM. Epithelial-mesenchymal transition (EMT) in tumor-initiating cells and its clinical implications in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15(2):253-60.
5. Cheng R, Sun B, Liu Z, Zhao X, Qi L, Li Y, et al. Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition. J Cell Physiol. 2014;229(12):1908-17.
6. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol. 2011;8(8):428-39.
7. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol. 2005;17(5):548-58.
8. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene. 2005;24(37):5764-74.
9. Levy L, Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2006;17(1-2):41-58.
10. Itesako T, Seki N, Yoshino H, Chiyomaru T, Yamasaki T, Hidaka H, et al. The microRNA expression signature of bladder cancer by deep sequencing: the functional significance of the miR-195/497 cluster. Plos One. 2014;9(2):e84311.
11. Hu Y, Tang H. MicroRNAs regulate the epithelial to mesenchymal transition (EMT) in cancer progression. MicroRNA. 2014;3(2):108-17.
12. Zhang H, Cai K, Wang J, Wang X, Cheng K, Shi F, et al. MiR-7, inhibited indirectly by LincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway. Stem Cells. 2014;32(11):2858-68.
13. Chen D, Huang J, Zhang K, Pan B, Chen J, De W, et al. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc. Eur J Cancer. 2014;50(17):3050-67.
14. Kato M, Zhang J, Wang M, Lanting L, Yuan H, Rossi JJ, et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A. 2007;104(9):3432-7.
15. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593-601.
16. Sun T, Wang X, He HH, Sweeney CJ, Liu SX, Brown M, et al. MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2014;33(21):2790-800.
17. Dentelli P, Traversa M, Rosso A, Togliatto G, Olgasi C, Marchio C, et al. miR-221/222 control luminal breast cancer tumor progression by regulating different targets. Cell Cycle. 2014;13(11):1811-26.
18. Qin J, Luo M. MicroRNA-221 promotes colorectal cancer cell invasion and metastasis by targeting RECK. FEBS Lett. 2014;588(1):99-104.
19. He XX, Guo AY, Xu CR, Chang Y, Xiang GY, Gong J, et al. Bioinformatics analysis identifies miR-221 as a core regulator in hepatocellular carcinoma and its silencing suppresses tumor properties. Oncol Rep. 2014;32(3):1200-10.
20. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al. Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007;25(5):387-92.
21. Lu Q, Lu C, Zhou GP, Zhang W, Xiao H, Wang XR. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol Oncol. 2010;28(6):635-41.
22. Liu B, Che W, Xue J, Zheng C, Tang K, Zhang J, et al. SIRT4 prevents hypoxia-induced apoptosis in H9c2 cardiomyoblast cells. Cell Physiol Biochem. 2013;32(3):655-62.
23. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2(2):329-33.
24. Hwang MS, Yu N, Stinson SY, Yue P, Newman RJ, Allan BB, et al. miR-221/222 targets adiponectin receptor 1 to promote the epithelial-to-mesenchymal transition in breast cancer. PLoS One. 2013;8(6):e66502.
25. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, et al. miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 2011;4(186):t5.
26. Baldassarre G, Belletti B, Nicoloso MS, Schiappacassi M, Vecchione A, Spessotto P, et al. p27(Kip1)-stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell. 2005;7(1):51-63.
27. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther. 2008;8(9):1461-70.
28. Akhtar J, Wang Z, Yu C, Li CS, Shi YL, Liu HJ. STMN-1 is a potential marker of lymph node metastasis in distal esophageal adenocarcinomas and silencing its expression can reverse malignant phenotype of tumor cells. BMC Cancer. 2014;14:28.
29. Byrne FL, Yang L, Phillips PA, Hansford LM, Fletcher JI, Ormandy CJ, et al. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. Oncogene. 2014;33(7):882-90.
30. Hsu HP, Li CF, Lee SW, Wu WR, Chen TJ, Chang KY, et al. Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumour Biol. 2014;35(3):2619-29.
31. Nemunaitis J. Stathmin 1: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets. 2012;16(7):631-4.
32. Williams K, Ghosh R, Giridhar PV, Gu G, Case T, Belcher SM, et al. Inhibition of stathmin1 accelerates the metastatic process. Cancer Res. 2012;72(20):5407-17.